Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy
Recruitment status was: Not yet recruiting
To identify the prevalence and severity of the fear of falling in a rheumatoid population
To explore the effect the treatment with biological agents has on fear of falling and physical activity in a rheumatoid population
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy|
- To identify the prevalence and severity of the fear of falling in a rheumatoid population
- To explore the effect the treatment with biological agents has on fear of falling and physical activity in a rheumatoid population
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||October 2010|
|Estimated Primary Completion Date:||October 2010 (Final data collection date for primary outcome measure)|
Rheumatoid Arthritis (RA) Patient Group
Patients with RA who have been refered for biological drug treatment
20 people of same age and sex as the RA patient cohort
The study will be an open, observational study to determine the prevalence of fear of falling in a rheumatoid population with severe disease being considered for biological therapy; this will be compared with physical activity levels at baseline and the change in these level pre and post treatment with biologic therapy. An age and sex matched control group will also be studied to allow inference to be drawn from the self reported 'fear of falling' and the objective activity levels of the RA population.
The study will consist of two visits: screening/baseline, and a 12 week follow up visit. It will be an observational study of the effects of the planned treatment regime via the NHS pathway. The subjects who are eligible to enter in the study will receive his/her normal treatment prescribed and be at the referral phase for biological treatment. The control group will continue on any existing treatments but will not have any reported physical limitations.
At the screening/baseline visit the self completion outcome questionnaires will be given to both the patient group and the control group. A disease activity score (aggregate score of RA symptoms - DAS) for the RA population will be calculated by a nurse specialist at the time of referral for the biological agent and again at 12 weeks post treatment, these parameters will not be repeated by the research team but the DAS score will be collected used in the final analysis. In addition, the Numact ambulatory activity recorder - used to assess spontaneous ambulatory activity - will be fitted for a 24hour period. This screening / baseline visit will occur before, but as near as possible to the 1st treatment day of the prescribed biological agent.
Occasionally the recording device may fail due to extraneous factors; in this instance a second recording may be required.
The control group will complete their study participation immediately after the screening / baseline visit.
The participant will then follow the care pathway of their treating physician with no interception by the study team. The 2nd and final study visit will be scheduled for 12 weeks post treatment with the biologic agent.
At 12 weeks a repeat assessment of the screening procedures will be made. Beyond which there will be no further study contact with the patients unless they request further discussion about the study findings. If they request this an appointment will be made at the time of the final study report/write up.
Physical examination could be carried out at any time during the study period if considered appropriate by the physician, however, this is not a predicted study procedure..
Details of any changes in medication and adverse events will be reported by subjects at the final visit, week 12.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01071863
|Newcastle upon Tyne NHS F Trust|
|Newcastle, UK, United Kingdom, NE7 7DN|
|Principal Investigator:||David J Walker, MD||Newcastle upon Tyne NHS Foundation Trust|